ImmunoCellular Therapeutics, Ltd.
IMUC
IMUC was delisted on the 16th of October, 2018.
28 hedge funds and large institutions have $4.76M invested in ImmunoCellular Therapeutics, Ltd. in 2015 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 7 closing their positions.
10% less funds holding
Funds holding: 31 → 28 (-3)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
24% less capital invested
Capital invested by funds: $6.26M → $4.76M (-$1.5M)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Bailard
Foster City,
California
|
+$435K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$12.5K |
| 3 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
+$12.3K |
| 4 |
NCCM
Nine Chapters Capital Management
Short Hills,
New Jersey
|
+$11.1K |
| 5 |
ACM
Alethea Capital Management
Mercer Island,
Washington
|
+$5.01K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$775K |
| 2 |
Renaissance Technologies
New York
|
-$237K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$166K |
| 4 |
CC
Callan Capital
La Jolla,
California
|
-$143K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
-$11.8K |
IMUC Hedge Fund Activity: Q3 2015 in Review
28 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in ImmunoCellular Therapeutics, Ltd. (IMUC) for Q3 2015, worth a combined $4.76M — down 24% from $6.26M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of IMUC and 4 opened new positions — a net loss of 3 holders — while 5 trimmed existing stakes and 4 added.
The largest buyer was Bailard, adding an estimated $435K. The largest seller was Sabby Management, cutting an estimated $775K.
- 28 institutional investors held ImmunoCellular Therapeutics, Ltd. (IMUC) as of Q3 2015, down from 31 in Q2 2015.
- Funds reported $4.76M of ImmunoCellular Therapeutics, Ltd. stock for Q3 2015, down 24% quarter-over-quarter.
- 4 funds opened new ImmunoCellular Therapeutics, Ltd. positions in Q3 2015 and 7 closed out, a net change of -3 holders.
- The largest ImmunoCellular Therapeutics, Ltd. buyer in Q3 2015 was Bailard, an estimated $435K added.
- The largest ImmunoCellular Therapeutics, Ltd. seller in Q3 2015 was Sabby Management, an estimated $775K sold.
Based on aggregated 13F filings for Q3 2015.